Tan-Koi WC - Search Results

1

Pharmacovigilance activities in ASEAN countries.

Suwankesawong W, Dhippayom T, Tan-Koi WC, Kongkaew C. Suwankesawong W, et al. Among authors: tan koi wc. Pharmacoepidemiol Drug Saf. 2016 Sep;25(9):1061-9. doi: 10.1002/pds.4023. Epub 2016 May 12. Pharmacoepidemiol Drug Saf. 2016. PMID: 27174034

2

Health regulatory communications of well-established safety-related pharmacogenomics associations in six developed countries: an evaluation of alignment.

Tan-Koi WC, Lim ES, Teo YY. Tan-Koi WC, et al. Pharmacogenomics J. 2017 Mar;17(2):121-127. doi: 10.1038/tpj.2016.5. Epub 2016 Feb 23. Pharmacogenomics J. 2017. PMID: 26902540

3

Tailoring of recommendations to reduce serious cutaneous adverse drug reactions: a pharmacogenomics approach.

Tan-Koi WC, Sung C, Chong YY, Lateef A, Pang SM, Vasudevan A, Aw D, Lui NL, Lee SX, Ren EC, Koay ES, Tay YK, Lim YL, Lee HY, Dong D, Loke C, Tan L, Limenta M, Lee EJ, Toh D, Chan CL. Tan-Koi WC, et al. Pharmacogenomics. 2017 Jun;18(9):881-890. doi: 10.2217/pgs-2017-0016. Epub 2017 Jun 8. Pharmacogenomics. 2017. PMID: 28594314

4

Role of pharmacogenetics in public health and clinical health care: a SWOT analysis.

Kapoor R, Tan-Koi WC, Teo YY. Kapoor R, et al. Among authors: tan koi wc. Eur J Hum Genet. 2016 Dec;24(12):1651-1657. doi: 10.1038/ejhg.2016.114. Epub 2016 Aug 31. Eur J Hum Genet. 2016. PMID: 27577547 Free PMC article. Review.

5

Pharmacogenetics through a public health lens: from policy to practice.

Tan-Koi WC, Kapoor R, Teo YY. Tan-Koi WC, et al. Pharmacogenet Genomics. 2015 Oct;25(10):518-20. doi: 10.1097/FPC.0000000000000159. Pharmacogenet Genomics. 2015. PMID: 26325520 No abstract available.

6

Cost-effectiveness analysis of genotyping for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore.

Dong D, Tan-Koi WC, Teng GG, Finkelstein E, Sung C. Dong D, et al. Among authors: tan koi wc. Pharmacogenomics. 2015 Nov;16(16):1781-93. doi: 10.2217/pgs.15.125. Epub 2015 Nov 10. Pharmacogenomics. 2015. PMID: 26554739

7

A cluster of Epoetin-associated pure red cell aplasia: clinical features and the possible association of HLA-DRB1*12:02.

Tan CW, Tan-Koi WC, Ng J, Chan CM, Hwang WY. Tan CW, et al. Among authors: tan koi wc. Pharmacogenomics. 2016 Jul;17(11):1235-1243. doi: 10.2217/pgs-2016-0018. Epub 2016 Jun 27. Pharmacogenomics. 2016. PMID: 27348021

8

Applications of pharmacogenomics in regulatory science: a product life cycle review.

Tan-Koi WC, Leow PC, Teo YY. Tan-Koi WC, et al. Pharmacogenomics J. 2018 May 22;18(3):359-366. doi: 10.1038/tpj.2017.47. Epub 2017 Dec 5. Pharmacogenomics J. 2018. PMID: 29205206 Review.

9

Is HLA-B*58:01 genotyping cost effective in guiding allopurinol use in gout patients with chronic kidney disease?

Teng GG, Tan-Koi WC, Dong D, Sung C. Teng GG, et al. Among authors: tan koi wc. Pharmacogenomics. 2020 Mar;21(4):279-291. doi: 10.2217/pgs-2019-0160. Epub 2020 Mar 17. Pharmacogenomics. 2020. PMID: 32180492

10

Regulation in the age of calamity: Changing the regulatory paradigm.

Hatchett R, Chan MXJ, Hacker A, Tan-Koi WC, Vogel S, Lim JC. Hatchett R, et al. Among authors: tan koi wc. Clin Transl Sci. 2024 Jul;17(7):e13882. doi: 10.1111/cts.13882. Clin Transl Sci. 2024. PMID: 38953176 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

11 results

Search Page

Filters